Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Achilles Therapeutics plc (ACHL)

1.6   -0.11 (-6.43%) 12-06 10:08
Open: 1.71 Pre. Close: 1.71
High: 1.72 Low: 1.6
Volume: 78,393 Market Cap: 66(M)

Technical analysis

as of: 2022-12-06 9:45:39 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.23     One year: 2.47
Support: Support1: 1.58    Support2: 1.31
Resistance: Resistance1: 1.91    Resistance2: 2.11
Pivot: 1.83
Moving Average: MA(5): 1.78     MA(20): 1.8
MA(100): 2.43     MA(250): 2.85
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 13.4     %D(3): 28.7
RSI: RSI(14): 40.6
52-week: High: 5.65  Low: 1.58
Average Vol(K): 3-Month: 50 (K)  10-Days: 22 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACHL ] has closed above bottom band by 13.7%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.85 - 1.86 1.86 - 1.87
Low: 1.69 - 1.7 1.7 - 1.71
Close: 1.69 - 1.71 1.71 - 1.73

Company Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Headline News

Tue, 06 Dec 2022
Achilles Therapeutics (ACHL) to Present Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022 -

Fri, 02 Dec 2022
Why UiPath Shares Are Trading Higher By Around 8%; Here Are 24 Stocks Moving Premarket By Benzinga - UK

Tue, 22 Nov 2022
Achilles Therapeutics Granted US Patent on Immunotherapy Targeting Clonal Neoantigens Identified Using Proprietary Method -

Tue, 22 Nov 2022
Health Care Sector Update for 11/22/2022: INNV,ACHL,MDT - Nasdaq

Fri, 18 Nov 2022
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation - Simply Wall St

Sun, 13 Nov 2022
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 41 (M)
Shares Float 12 (M)
% Held by Insiders 4.9 (%)
% Held by Institutions 73.5 (%)
Shares Short 72 (K)
Shares Short P.Month 53 (K)

Stock Financials

EPS 6.34
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.94
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.7
Return on Equity (ttm) -25.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.72
Qtrly Earnings Growth 0
Operating Cash Flow -54 (M)
Levered Free Cash Flow -41 (M)

Stock Valuations

PE Ratio 0.26
PEG Ratio -0.4
Price to Book value 0.34
Price to Sales 0
Price to Cash Flow -1.28

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.